Guidelines for Drug Donations - Revised 1999
(1999; 24 pages) [French] [Spanish] Voir le document au format PDF
Table des matières
Afficher le documentChanges incorporated into the 1999 edition
Afficher le documentI. Introduction
Afficher le documentII. The need for guidelines
Afficher le documentIII. Core principles
Fermer ce répertoireIV. Guidelines for drug donations
Afficher le documentSelection of drugs
Afficher le documentQuality assurance and shelf-life
Afficher le documentPresentation, packing and labelling
Afficher le documentInformation and management
Ouvrir ce répertoire et afficher son contenuV. Other ways donors can help
Ouvrir ce répertoire et afficher son contenuVI. How to implement a policy on drug donations
Afficher le documentAnnex: Examples of problems with drug donations
Afficher le documentAcknowledgements
Afficher le documentReferences
Afficher le documentBack Cover

Information and management

10. Recipients should be informed of all drug donations that are being considered, prepared or actually under way.

Justification and explanation

Many drug donations arrive unannounced. Detailed advance information on all drug donations is essential to enable the recipient to plan for the receipt of the donation and to coordinate the donation with other sources of supply. The information should at least include: the type and quantities of donated drugs including their International Nonproprietary Name (INN) or generic name, strength, dosage form, manufacturer and expiry date; reference to earlier correspondence (for example, the letter of consent by the recipient); the expected date of arrival and port of entry; and the identity and contact address of the donor.

11. In the recipient country the declared value of a drug donation should be based upon the wholesale price of its generic equivalent in the recipient country, or, if such information is not available, on the wholesale world-market price for its generic equivalent.

Justification and explanation

This provision is needed solely to prevent drug donations being valued in the recipient country according to the retail price of the product in the donor country. This may lead to elevated overhead costs for import tax, port clearance and handling in the recipient country. It may also result in a corresponding decrease in the public sector drug budget in the recipient country.

Possible exception

In the case of patented drugs (for which there is no generic equivalent) the wholesale price of the nearest therapeutic equivalent could be taken as a reference.

12. Costs of international and local transport, warehousing, port clearance and appropriate storage and handling should be paid by the donor agency, unless specifically agreed otherwise with the recipient in advance.

Justification and explanation

This provision prevents the recipient from being forced to spend effort and money on the clearance and transport of unannounced consignments of unwanted items, and also enables the recipient to review the list of donated items at an early stage.

vers la section précédente
vers la section suivante
Le Portail d'information - Médicaments essentiels et produits de santé a été conçu et est maintenu par l'ONG Human Info. Dernière mise à jour: le 20 mars 2014